Art. -Nr.: HY-113974

trans-AUCB

(Synonyms: t-AUCB)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 95.66%
CAS. Nr.: 885012-33-9
Formel: C₂₄H₃₂N₂O₄
Molecular Weight:412.52

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

trans-AUCB Chemical Structure

CAS. Nr.: 885012-33-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 1.3 nM (hsEH), 8 nM (mouse sEH) and 8 nM (rat sEH)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	GI₅₀	>25 μM Compound: 11, t-AUCB	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23726028]
Huh-7	GI₅₀	>25 μM Compound: 11, t-AUCB	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 23726028]
HUVEC	GI₅₀	>25 μM Compound: 11, t-AUCB	Antiproliferative activity against HUVEC after 72 hrs by MTT assay Antiproliferative activity against HUVEC after 72 hrs by MTT assay	[PMID: 23726028]
Sf21	IC₅₀	0.5 nM Compound: t-AUCB	Inhibition of recombinant human liver soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay Inhibition of recombinant human liver soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay	[PMID: 31488357]

In Vitro

trans-AUCB (t-AUCB; 25-300 μM; 48 hours) suppresses U251 and U87 cell growth in a dose-dependent manner^[1].
trans-AUCB (200 μM; 48 or 96 hours) induces cell-cycle G0/G1 phase arrest in U251 and U87 cells^[1].
trans-AUCB (200 μM; 10 min-4 hours) can increase the phosphorylation levels of p65 after 10 min, reaching to peak after 30 min and lasting for at least 2 hours^[1].
trans-AUCB (200 μM; 48 hours) suppresses U251 and U87 cell growth by activating NF-jB-p65^[1].
trans-AUCB (10 μM; 30 min) efficiently inhibits sEH activities in human glioblastoma cell lines (U251, U87) and human hepatocellular carcinoma cell line (HepG2 cells)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

U251, U87 cells
Concentration:

25, 50, 100, 200, or 300 μM
Incubation Time:

48 hours
Result:

Suppressed U251 and U87 cell growth in a dose-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:

U251, U87 cells
Concentration:

200 μM
Incubation Time:

48 or 96 hours
Result:

Induced cell-cycle G0/G1 phase arrest in U251 and U87 cells.

Western Blot Analysis^[1]

Cell Line:

U251, U87 cells
Concentration:

200 μM
Incubation Time:

10 min, 30 min, 1 hour, 2 hours, or 4 hours
Result:

Increased the phosphorylation levels of p65 after 10 min, reached to peak after 30 min and lasted for at least 2 hours.

In Vivo

trans-AUCB (t-AUCB; p.o.; 0.1, 0.5, 1 mg/kg) ameliorates the LPS-induced hypotension in a dose-dependent manner^[2].
trans-AUCB (p.o.; 0.1, 0.5, 1 mg/kg) has t_1/2 values of 20, 30, 15 min and C_max values of 30, 100, 150 nmol/L for p.o. of 0.1, 0.5, 1 mg/kg^[2].
trans-AUCB (s.c.; 1, 3, 10 mg/kg) has t_1/2 values of 60, 85, 75 min and C_max values of 245, 2700, 3600 nmol/L for s.c. of 1, 3, 10 mg/kg^[2].
trans-AUCB (i.v.; 0.1 mg/kg) has t_1/2 values of 70 min and 10 hours for distribution (α) and elimination (β) phases. trans-AUCB has a CL of 0.7 L/h kg and a V_dss was 17 L/kg^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice (male CFW strain, 7 weeks old, 24-30 g; and male C57BL/6 strain, 8 weeks old, 22-25 g) ^[2]
Dosage:

0.1, 0.5, 1 mg/kg
Administration:

PO
Result:

Ameliorated the LPS-induced hypotension in a dose-dependent manner.

Animal Model:

Mice (male CFW strain, 7 weeks old, 24-30 g; and male C57BL/6 strain, 8 weeks old, 22-25 g) ^[2]
Dosage:

0.1, 0.5, 1 mg/kg (Pharmacokinetic Analysis)
Administration:

PO
Result:

Had t_1/2 values of 20, 30, 15 min and C_max values of 30, 100, 150 nmol/L for p.o. of 0.1, 0.5, 1 mg/kg, respectively.

Chemical Information

CAS. Nr. 885012-33-9
Appearance Solid
Molecular Weight 412.52
Formel C₂₄H₃₂N₂O₄
Color White to off-white
SMILES

OC(C(C=C1)=CC=C1O[C@@H](CC2)CC[C@H]2NC(NC34C[C@H](C5)C[C@H](C[C@H]5C4)C3)=O)=O
Synonyms

t-AUCB
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Redox Biol

Endogenous acrolein accumulation in akr7a3 mutants causes microvascular dysfunction due to increased arachidonic acid metabolism. [Abstract]

2025 Jun:83:103639. PMID: 40258306
Mol Metab

CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. [Abstract]

2022 Feb:56:101426. PMID: 34971802

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (242.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4241 mL

12.1206 mL

24.2412 mL

5 mM

0.4848 mL

2.4241 mL

4.8482 mL

10 mM

0.2424 mL

1.2121 mL

2.4241 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li J, et al. t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activatingNF-κB-p65. J Neurooncol. 2012 Jul;108(3):385-93. [Content Brief]

[2]. Liu JY, et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murinemodel of inflammation. Br J Pharmacol. 2009 Jan;156(2):284-96. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4241 mL	12.1206 mL	24.2412 mL	60.6031 mL
	5 mM	0.4848 mL	2.4241 mL	4.8482 mL	12.1206 mL
	10 mM	0.2424 mL	1.2121 mL	2.4241 mL	6.0603 mL
	15 mM	0.1616 mL	0.8080 mL	1.6161 mL	4.0402 mL
	20 mM	0.1212 mL	0.6060 mL	1.2121 mL	3.0302 mL
	25 mM	0.0970 mL	0.4848 mL	0.9696 mL	2.4241 mL
	30 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0201 mL
	40 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5151 mL
	50 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2121 mL
	60 mM	0.0404 mL	0.2020 mL	0.4040 mL	1.0101 mL
	80 mM	0.0303 mL	0.1515 mL	0.3030 mL	0.7575 mL
	100 mM	0.0242 mL	0.1212 mL	0.2424 mL	0.6060 mL

Keywords

trans-AUCB

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

trans-AUCB

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) trans-AUCB

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

trans-AUCB

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) trans-AUCB

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

trans-AUCB Related Classifications

HY-113974 Related Classifications